- Trials with a EudraCT protocol (14)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
14 result(s) found for: Muscle Fiber.
Displaying page 1 of 1.
EudraCT Number: 2015-000578-37 | Sponsor Protocol Number: NL50679.068.15 | Start Date*: 2015-05-20 |
Sponsor Name:Maastricht University Medical Centre+ | ||
Full Title: The effect of Nandrolone Decanoate Injection and Leucine Supplementation on Muscle Loss During Immobilisation | ||
Medical condition: Muscle disuse atrophy | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2022-003359-33 | Sponsor Protocol Number: MABS06 | Start Date*: 2023-06-21 | |||||||||||
Sponsor Name:MUMC | |||||||||||||
Full Title: Assess efficacy of intra-arterial autologous myogenic stem cell therapy for m.3243A>G mutation carriers | |||||||||||||
Medical condition: Mitochondrial myopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-005103-27 | Sponsor Protocol Number: BETASBMA | Start Date*: 2021-11-18 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI PADOVA | |||||||||||||
Full Title: A PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CLENBUTEROL IN PATIENTS WITH SPINAL AND BULBAR MUSCULAR ATROPHY (SBMA) | |||||||||||||
Medical condition: Motor neuron disease characterized by atrophy and muscle weakness in the spinal and bulbar region | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000078-27 | Sponsor Protocol Number: SRP-9001-102 | Start Date*: 2022-11-10 | |||||||||||
Sponsor Name:Sarepta Therapeutics, Inc. | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial for Duchenne Muscular Dystrophy Using SRP-9001 | |||||||||||||
Medical condition: Duchenne Muscular Dystrophy | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002069-52 | Sponsor Protocol Number: 4045-301 | Start Date*: 2017-01-23 | |||||||||||
Sponsor Name:Sarepta Therapeutics, Inc. | |||||||||||||
Full Title: A Double-Blind, Placebo-Controlled, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy | |||||||||||||
Medical condition: Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Ongoing) SE (Completed) DE (Completed) FR (Ongoing) ES (Ongoing) CZ (Ongoing) NL (Ongoing) IT (Ongoing) BG (Ongoing) PL (Ongoing) IE (Ongoing) DK (Ongoing) GR (Ongoing) NO (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-005001-39 | Sponsor Protocol Number: 4658-us-202 | Start Date*: 2017-03-16 | |||||||||||
Sponsor Name:Sarepta Therapeutics, Inc. | |||||||||||||
Full Title: Open-Label, Multiple-Dose, Efficacy, Safety, and Tolerability Study of Eteplirsen in Subjects with Duchenne Muscular Dystrophy who Participated in Study 4658-us-201 | |||||||||||||
Medical condition: Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003934-16 | Sponsor Protocol Number: 1301-01 | Start Date*: 2012-08-01 | |||||||||||
Sponsor Name:Pluristem Ltd. | |||||||||||||
Full Title: A Phase I/II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Intramuscular Injections of Allogeneic PLX-PAD Cells for the Regeneration of Injured Gluteal Mu... | |||||||||||||
Medical condition: Regeneration of injured Gluteal Musculature (GM) after Total Hip Arthroplasty (THA) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001340-25 | Sponsor Protocol Number: UMC-NMZ-EPHENE2020 | Start Date*: 2020-07-17 | |||||||||||
Sponsor Name:University Medical Center Utrecht | |||||||||||||
Full Title: Enrichment randomized double-blind, placebo-controlled cross-over trial with PHEnytoin cream in patients with painful chronic idiopathic axonal polyNEuropathy | |||||||||||||
Medical condition: Painful chronic idiopathic axonal polyneuropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020611-36 | Sponsor Protocol Number: AGLU07310 | Start Date*: 2011-10-12 | |||||||||||
Sponsor Name:Genzyme Europe B.V. | |||||||||||||
Full Title: A Phase 4 Prospective Exploratory Muscle Biopsy, Biomarker, and Imaging Assessment Study in Patients With Late-Onset Pompe Disease Treated With Alglucosidase Alfa | |||||||||||||
Medical condition: Pompe disease (acid alpha-glucosidase deficiency) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002938-73 | Sponsor Protocol Number: ARGX-113-1602 | Start Date*: 2016-10-31 | |||||||||||
Sponsor Name:Argenx BVBA | |||||||||||||
Full Title: A Randomized, Double blind, Placebo Controlled Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX 113 in Patients with Myasthenia Gravis who have Generalized Muscle Weakness | |||||||||||||
Medical condition: Myasthenia Gravis who have Generalized Muscle Weakness | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) SE (Completed) ES (Completed) NL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-003407-15 | Sponsor Protocol Number: SRP-9001-104 | Start Date*: 2023-08-08 |
Sponsor Name:Sarepta Therapeutics, Inc | ||
Full Title: An Open-Label, Systemic Gene Delivery Study to Evaluate the Safety, Tolerability and Expression of SRP-9001 in association with imlifidase in Subjects with Duchenne Muscular Dystrophy with pre-exis... | ||
Medical condition: Duchenne muscular dystrophy | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male | |
Trial protocol: ES (Temporarily Halted) | ||
Trial results: (No results available) |
EudraCT Number: 2021-003898-59 | Sponsor Protocol Number: EFC17262 | Start Date*: 2021-11-12 | |||||||||||
Sponsor Name:SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT | |||||||||||||
Full Title: A Phase 3, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of tolebrutinib (SAR442168) in adults with generalized myasthenia gravis (MG) | |||||||||||||
Medical condition: Myasthenia gravis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) ES (Prematurely Ended) PL (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005749-30 | Sponsor Protocol Number: 2015-00887 | Start Date*: 2016-06-23 | |||||||||||
Sponsor Name:Karolinska Institutet | |||||||||||||
Full Title: A randomized, doubleblind, placebo-controlled multicenter trial to evaluate the safety and efficacy of rituximab (Mabthera) in subjects with new onset myasthenia gravis; the RINOMAX study | |||||||||||||
Medical condition: New onset myasthenia gravis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004085-19 | Sponsor Protocol Number: ARGX-113-2001 | Start Date*: 2021-02-24 | |||||||||||
Sponsor Name:argenx BV | |||||||||||||
Full Title: A Phase 3, Randomized, Open-Label, Parallel-Group Study to Compare the Pharmacodynamics, Pharmacokinetics, Efficacy, Safety, Tolerability, and Immunogenicity of Multiple Subcutaneous Injections of ... | |||||||||||||
Medical condition: Generalized Myasthenia Gravis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) NL (Completed) BE (Ongoing) DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.